Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis in Routine Clinical Setting in the Russian Federation

NCT02282982 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT02282982
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02282982 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis in Routine Clinical Setting in the Russian Federation
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
October 31, 2014
Completion date
May 31, 2015
Enrollment
359 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial virus (rsv)